Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Noxon
Israelnoxonschools.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Noxon is developing 3-cabamoyl-proxyl ("3-CP"), an orally administered small molecule from the nitroxide class with unique antioxidant properties. In preclinical animal models, 3-CP reduced airway inflammation and fibrosis associated with oxidative damage. The company targets idiopathic pulmonary fibrosis and other fibrotic lung diseases where current therapies are limited or have significant side effects. No human clinical data reported.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Small moleculeStable organic radical/nitroxide
- Industry
- Biotech
Beyond the preview
Go deeper on Noxon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noxon.